Retagliptin is a DPP-4 inhibitor potentially used to treat Type 2 diabetes.

SJA6017 is a inhibitor of calpain-1 (IC50 = 7.5 nM) and calpain-2 ( IC50 = 78 nM). SJA6017 also inhibits cathepsins B (IC50s = 15 nM) and cathepsins L (IC50s = 1.6 nM). SJA6017 reduces apoptotic cell death, preserves spinal cord tissue and improves functi

TM-1是一种有效的 26S 蛋白酶体抑制剂及自噬诱导剂。它能显著上调 LC3-II 水平并抑制肿瘤细胞增殖，通过双重调节降解通路发挥强效抗癌作用，常用于多发性骨髓瘤研究。

Calpain substrate 是一种膜不透性的荧光钙蛋白酶底物，用于钙蛋白酶酶活性的测定。

Immunoproteasome inhibitor 1 is a highly potent and reversible inhibitor of both immunoproteasome and proteasome activity. It exhibits time-independent inhibitory effects on immunoproteasome subunits β5c, β1i, and β5i, with respective Ki values of 1.18 μM, 0.27 μM, and 1.91 μM. This compound shows promising potential for the treatment of select neoplastic diseases [1].

2-Methoxy-5-acetoxy-furanogermacr-1(10)-en-6-one is a natural product

MyoMed-205 是一种MuRF1(肌肉环指蛋白1) 活性抑制剂。它可以防止单侧膈神经去神经12小时后引起的早期膈肌收缩功能障碍和萎缩。通过抑制MuRF1活性，MyoMed-205 减少了肌肉蛋白的泛素化和后续的蛋白酶体降解。此外，MyoMed-205 能提高磷酸化Akt(ser473)的蛋白水平，Akt对肌肉的生长和维持至关重要。MyoMed-205 适用于研究和治疗由早期失用引起的膈肌功能障碍和萎缩(DIDD)，尤其是在膈肌麻痹或机械通气等临床情况下。

Fotagliptin benzoate，作为一种二肽基肽酶IV (DPP-4) 抑制剂（IC50=2.27 nM），在大鼠和狗中展现了安全性，适用于2型糖尿病的研究。

KZR-504 is a selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2) (IC50s: 51 nM, 4.274 μM for LMP2 and LMP7, respectively).